Concentrix 10-Q Confirms $1.05B Goodwill Impairment and $988M Q3 Loss
CNXC sits 30% above its 52-week low of $19.12.
Summary
Concentrix filed its Q3 10-Q, confirming the $1.05B goodwill impairment and $988M GAAP loss previously disclosed, with additional detail on restructuring, debt, and liquidity.
Key Events · Earnings and Guidance · CNXC
-
Goodwill Impairment Drives Q3 Loss
Non-cash goodwill impairment of $1.05B drove a Q3 GAAP net loss of $988M, or $16.24 per share, versus net income of $88.1M a year ago.
-
Non-GAAP EPS Beats Expectations
Non-GAAP diluted EPS was $2.92 for Q3, exceeding the previously guided range of $2.86 to $2.98.
-
Restructuring Affects 30,000 Employees
Severance costs totaled $31.4M for Q3 and $91.7M for the nine months, with remaining cash payments expected to be substantially completed by November 30, 2026.
-
Securitization Facility Expanded
The receivables securitization facility commitment was increased from $700M to $750M and its termination date extended to March 20, 2028.
Analysis · CNXC · Trade & Services
The 10-Q formalizes the previously announced Q3 results, adding full balance sheet and cash flow detail. The $1.05B non-cash goodwill impairment drove a $988M GAAP net loss, while non-GAAP EPS of $2.92 beat expectations. Restructuring costs of $91.7M year-to-date affected 30,000 employees, and the company extended its securitization facility to $750M. The retained deficit now stands at $1.16B, and stockholders' equity fell to $1.77B from $2.74B at fiscal year-end.
How filings like this one have moved
In the 30 days to Oct 7, 2026, 29% of the 1648 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.62%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNXC was trading at $24.80 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $19.12 to $49.37. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.